Skip to Main Content
I'm looking for

Important product launches during Q2

Mölnlycke sales grew by 1% in constant currency during the second quarter of 2017. Both Wound Care and Surgical grew, although at a lower rate than in the same period last year, which was exceptionally strong for the company.

Mepilex border sacrum

Läs svenska vensionen här.

 Growth markets continue to develop strongly but growth in the US was slightly lower than expected. Sales fell slightly in Europe, mainly due to reduced levels of reimbursement in some markets.The EBITA margin was lower than in Q2 2016, due to the changes in reimbursement, higher costs for raw material and continuous investments in sales, marketing, product development and innovation.

During the quarter Mölnlycke successfully introduced new products within the areas of pressure ulcer prevention and post-operative wound management. Mölnlycke also started up a new production site for surgical procedure trays in the Czech republic. The investment of 67 Million EUR is the largest single investment in the company’s history.

 'The important product launches we have made during the quarter are the result of our focus on product development and innovation – and they have been received very positively by our customers,’ says Richard Twomey, CEO.

 'We also globally launched new products from businesses we acquired during 2016 in the US. In addition, we inaugurated our new modern, highly automated production site in the Czech republic which will improve our efficiency and increase the flexibility of our customer offer’.

Read Investor AB:s quarterly report for April-June 2017 here.


For more information please contact:

Stefan Fristedt, Executive Vice President and CFO
Tel. 031- 352 3746 , email:

Bodil Czarnecki, Global Manager Corporate Communications
Tel. 031-722 3037, email:

Contact us
Select market

Select market